Explore the Scientific R&D Platform

Free Trial

Sample Size & Power Calculations
Calculate for a Variety of frequentist and Bayesian Design

Adaptive Design
Design and Analyze a Wide Range of Adaptive Designs

Milestone Prediction
Predict Interim Analysis Timing or Study Length

Randomization Lists
Generate and Save Lists for your Trial Design


Group Sequential and Promising Zone Designs
Calculate Boundaries & Find Sample Size. Evaluate Interim Data & Re-estimate Sample Size

Sample Size for Bayesian Statistics
Probability of Success (Assurance), Credible Intervals, Bayes Factors and more

Early Stage and Complex Designs
Sample size & operating characteristics for Phase I, II & Seamless Designs (MAMS)

Free Trial

Sample Size Determination Example

AREA: Means | Cardiology

nQuery In Use Background Web  Opacity 35

BMS Diabetes Research

TitleCo-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes. A randomized, double-blind, placebo-controlled trial.

Objective: The immunopathogenesis of type 1 diabetes mellitus is associated with T-cell autoimmunity. To be fully active, immune T cells need a co-stimulatory signal in addition to the main antigen-driven signal. Abatacept modulates co-stimulation and prevents full T-cell activation. We evaluated the effect of abatacept in recent-onset type 1 diabetes.

Year: 2011

Source: The Lancet

Link: http://www.sciencedirect.com/science/article/pii/S0140673611608866

Clinical Area:  Cardiology

Sample Size Section in Paper/Protocol:

“Among baseline subjects, the mean log(c-peptide + 1) values are 0.248 with RMSE =0.179. The corresponding geometric-like mean C-peptide value is 0.282 pmol/mL obtained using the inverse transformation exp(0.248) – 1. Using standard equations it was determined that a sample size of 108 subjects randomized to active treatment versus placebo in a 2:1 ratio would provide power of 85% to detect a 50% increase in the geometric-like mean C-peptide with the active treatment related to the placebo group using a test at the 0.05 level (one-sided), with 10% loss to follow-up. Interim analysis for endpoint treatment effect was done and reported to the data and safety monitoring board once in accordance to the method of Lan and DeMets with O'Brien-Fleming boundaries.”

Summary of Necessary Parameter Estimates for Sample Size Calculation:

 Parameter Value
 Significance Level 0.05
 Expected Placebo Mean 0.248
 Expected Treatment Mean 0.353
 Common Standard Deviation (RMSE) 0.179
 Power 85%
Number of Interim Analyses 1
Dropout 10%

Email me this example in PDF format

Step 1:
Select the Group Sequential Test of Two Mean Table from the Select Test Design & Goal window.

This can be done using the radio buttons or alternatively, you can use the search bar at the end of the Select Test Design & Goal window.


Sample Size Calculator Example- nQuery- Example 06- Img 01- Group Sequential Test of Two Means

Step 2:
Enter the values for sample size calculation taken from the study design statement.

Setting the “Number of looks” row to 2 specifies one interim analysis and one endpoint analysis.

The O’Brien Fleming boundaries will be selected by default. No futility analysis was included in this study.

Set the standard deviation in both groups to the same value to indicate a common variances solution.

Sample Size Calculator Example- nQuery- Example 06- Img 02- Group Sequential Test of Two Means

Step 3:
Click Run to solve for sample size

The analysis gives a sample size of 32 and 64 giving 82.4% power.

The sample sizes adjusted for dropout were 36 and 72 (sample sizes divided by 0.9).

This gives the total sample size of 108 given in the study design.


Sample Size Calculator Example- nQuery- Example 06- Img 03- Group Sequential Test of Two Means

Step 4:
Once the calculation is completed, nQuery Advanced provides an output statement summarizing the results. It States:

Output Statement:

Sample sizes of 32 in group 1 and 64 in group 2 are required to achieve 85.41% power to detect a difference in means of -0.105 (the difference between group 1 mean, μ1, of 0.248 and group 2 mean, μ2, of 0.353) assuming that the standard deviation in group 1 is 0.179 and in group 2 is 0.179 using a one-sided z-test with 5% significance level. These results assume that the group sequential design has 1 interim sequential tests (2 total interim looks including final analysis) and the O'Brien-Fleming spending function is used to determine the efficacy test boundary.

The drift parameter for this design equals 2.709. The drift parameter defines the increase in sample size needed over a fixed term design and equals square root of the maximum information level by the difference.


Sample Size Calculator Example- nQuery- Example 06- Img 04- Group Sequential Test of Two Means

Step 5:
nQuery Advanced also provides graphs and the details of the interim analysis.

Sample Size Calculator Example- nQuery- Example 06- Img 05- Group Sequential Test of Two Means

Email me this example in PDF format

Free 14 Day Trial

Demo Icon white
No download required